Quantcast

Attention Galectin Therapeutics Inc. Investors: Galectin Misled Investors According to a Recently Filed Class Action - 12 News KBMT and K-JAC. News, Weather and Sports for SE Texas

Attention Galectin Therapeutics Inc. Investors: Galectin Misled Investors According to a Recently Filed Class Action

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Robbins Arroyo LLP

SAN DIEGO and NORCROSS, Ga., Aug. 1, 2014 /PRNewswire/ -- Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Galectin Therapeutics Inc. (NASDAQ: GALT) has filed a federal securities fraud class action complaint in the U.S. District Court for the District of Nevada. The complaint alleges that the company and certain of its officers and directors violated the Securities Exchange Act of 1934 between January 6, 2014 and July 28, 2014 (the "Class Period"). Galectin is a development stage company that researches and develops therapies for fibrotic disease and cancer.

Robbins Arroyo LLP.

Galectin Is Accused of Engaging in a Misleading Promotional Campaign

According to the complaint, on July 28, 2014, Bleecker Street Research published an article on SeekinAlpha.com claiming Galectin had "strong ties to stock promoters" and was engaging in a misleading brand awareness campaign. On the same day, Adam Feuerstein published an article on TheStreet.com detailing Galectin's alleged association with penny-stock promotions firm Emerging Growth Corp., through its parent company TDM Financial. Through this relationship, Galectin engaged in a misleading promotional campaign to encourage investors to purchase stock of Galectin. On this news, Galectin's stock dropped nearly 61% to close at $5.70, trading at unusually high volumes.

Galectin Investors Are Encouraged to Contact Shareholder Rights Law Firm Robbins Arroyo LLP

If you invested in Galectin and would like to discuss your shareholder rights, please contact attorney Darnell R. Donahue at (800) 350-6003, DDonahue@robbinsarroyo.com, or via the information form on the firm's shareholder rights blog: www.robbinsarroyo.com/shareholders-rights-blog/galectin-therapeutics-inc.

Robbins Arroyo LLP is a nationally recognized leader in securities litigation and shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contact:
Darnell R. Donahue
Robbins Arroyo LLP
DDonahue@robbinsarroyo.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsarroyo.com

Logo - http://photos.prnewswire.com/prnh/20130103/MM36754LOGO

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow

Newsroom: (409) 838-1212
Front Desk: (409) 833-7512
News Fax: (409) 981-1564
News Email: 12News@kbmt12.com

Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and KBMT. All Rights Reserved.
Users of this site agree to the Terms of Service, Privacy Notice/Your California Privacy Rights, and Ad Choices.